NYSE:JNJ
147.55
0.85
(0.57%)
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886.
More at Wikipedia
Johnson & Johnson
JNJ-N
Analysis and Opinions about JNJ-N
Signal
Opinion
Expert
BUY
BUY
PAST TOP PICK
PAST TOP PICK
July 10, 2020
(A Top Pick Jul 29/19, Up 10%) He would stick with this one. When a vaccine comes forward, he expects them to bounce up. His model price is $203 -- over 40% upside.
(A Top Pick Jul 29/19, Up 10%) He would stick with this one. When a vaccine comes forward, he expects them to bounce up. His model price is $203 -- over 40% upside.
COMMENT
COMMENT
June 12, 2020
JNJ vs ABBV? He likes JNJ as a long term winner. It may be too expensive. ABBV was a risky company until they purchased Allergan and diversified their business more. ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. They are still tethered to Humara, which has a lot of generics being developed. He would favor ABBV, although it is a little riskier than JNJ.
JNJ vs ABBV? He likes JNJ as a long term winner. It may be too expensive. ABBV was a risky company until they purchased Allergan and diversified their business more. ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. They are still tethered to Humara, which has a lot of generics being developed. He would favor ABBV, although it is a little riskier than JNJ.
PAST TOP PICK
PAST TOP PICK
June 8, 2020
(A Top Pick May 22/19, Up 9%) He likes the pharma and medical devices areas. He bought when it was suffering from a couple of law suits. They are a minor player in the affected sectors. He likes the healthcare sector.
Show full opinionHide full opinion(A Top Pick May 22/19, Up 9%) He likes the pharma and medical devices areas. He bought when it was suffering from a couple of law suits. They are a minor player in the affected sectors. He likes the healthcare sector.
TOP PICK
TOP PICK
May 11, 2020
It is three different companies: a medical device division; personal care division; and the pharmaceutical division. It continues to execute very well. They are not dependent on their pipeline of drugs. You have a great opportunity to buy a diversified company. There have been some risks on products like talcum powder but they are very good at defending themselves. (Analysts’ price target is $162.10)
Show full opinionHide full opinionIt is three different companies: a medical device division; personal care division; and the pharmaceutical division. It continues to execute very well. They are not dependent on their pipeline of drugs. You have a great opportunity to buy a diversified company. There have been some risks on products like talcum powder but they are very good at defending themselves. (Analysts’ price target is $162.10)
BUY
BUY
May 7, 2020
An excellent company and raised its dividend 55 years in a row. It has done a fantastic job and is a diversified healthcare stock. They have benefited from COVD-19. It is one of the better companies. This gets is whole-hearted support right now.
Show full opinionHide full opinionAn excellent company and raised its dividend 55 years in a row. It has done a fantastic job and is a diversified healthcare stock. They have benefited from COVD-19. It is one of the better companies. This gets is whole-hearted support right now.
TOP PICK
TOP PICK
March 30, 2020
He would be a buyer here as it has dropped so much from the last time he recommended it. They announced they have something related to COVID-19 vaccination and can start human trials in late September. (Analysts’ price target is $157.85)
Show full opinionHide full opinionHe would be a buyer here as it has dropped so much from the last time he recommended it. They announced they have something related to COVID-19 vaccination and can start human trials in late September. (Analysts’ price target is $157.85)
TOP PICK
TOP PICK
March 12, 2020
Defensive. One of the largest healthcare companies in the world. Medical devices, pharma, personal care products. Great story. Consistent dividend grower. Talcum litigation issue has been dealt with. Very stable company. Yield is 3.03%. (Analysts’ price target is $159.84)
Show full opinionHide full opinionDefensive. One of the largest healthcare companies in the world. Medical devices, pharma, personal care products. Great story. Consistent dividend grower. Talcum litigation issue has been dealt with. Very stable company. Yield is 3.03%. (Analysts’ price target is $159.84)
TOP PICK
TOP PICK
February 28, 2020
It's been sideways for a couple years. This week, it shot down but he believes it will get back out to where it was before. It can definitely break out after recovery. They have more divisions than just pharma, like pet items. (Analysts’ price target is $160.28)
Show full opinionHide full opinionIt's been sideways for a couple years. This week, it shot down but he believes it will get back out to where it was before. It can definitely break out after recovery. They have more divisions than just pharma, like pet items. (Analysts’ price target is $160.28)
TOP PICK
TOP PICK
February 27, 2020
Model price is $182.97 or 28% upside. He likes the company and thinks it has good upside. (Analysts’ price target is $160.28)
Show full opinionHide full opinionModel price is $182.97 or 28% upside. He likes the company and thinks it has good upside. (Analysts’ price target is $160.28)
PAST TOP PICK
PAST TOP PICK
February 26, 2020
(A Top Pick Dec 16/19, Up 2%) A defensive name but durable. You're paid to wait. This applies to his other two past picks today, too.
Show full opinionHide full opinion(A Top Pick Dec 16/19, Up 2%) A defensive name but durable. You're paid to wait. This applies to his other two past picks today, too.
PAST TOP PICK
PAST TOP PICK
January 21, 2020
(A Top Pick Nov 19/19, Up 11%) The gains have surprised him. Good. If you're holding long-term, continue to hold. If you're trading this, you can do it now.
Show full opinionHide full opinion(A Top Pick Nov 19/19, Up 11%) The gains have surprised him. Good. If you're holding long-term, continue to hold. If you're trading this, you can do it now.
BUY
BUY
January 14, 2020
Has long owned this. It's attractively valued in this space. Likes their diversity--pharmaceutical (many new products), medical devices, and consumer products. Litigation overhang (talcum powder lawsuit) is an overhang. JNJ continues to raise their 3% dividend. Has a strong balance sheet. You can start buying it here if you are a long-term investor.
Show full opinionHide full opinionHas long owned this. It's attractively valued in this space. Likes their diversity--pharmaceutical (many new products), medical devices, and consumer products. Litigation overhang (talcum powder lawsuit) is an overhang. JNJ continues to raise their 3% dividend. Has a strong balance sheet. You can start buying it here if you are a long-term investor.
TOP PICK
TOP PICK
January 10, 2020
His model price is $190.40 -- over 30% upside, he believes. He does not expect the talc problem to an issue and creates a great opportunity to buy in. Yield 2.6% (Analysts’ price target is $156.06)
Show full opinionHide full opinionHis model price is $190.40 -- over 30% upside, he believes. He does not expect the talc problem to an issue and creates a great opportunity to buy in. Yield 2.6% (Analysts’ price target is $156.06)
TOP PICK
TOP PICK
January 8, 2020
In an election year, these kind of stocks get beaten, but JNJ is highly diversified in three divisions including personal products and are not merely into drugs which is a target of politicians in a US election year. JNJ has raised its dividend in each of the past 50 years. Trades at a decent 16x earnings. JNJ faces many lawsuits, but they staunchly defend themselves through appeals. (Analysts’ price target is $154.41)
Show full opinionHide full opinionIn an election year, these kind of stocks get beaten, but JNJ is highly diversified in three divisions including personal products and are not merely into drugs which is a target of politicians in a US election year. JNJ has raised its dividend in each of the past 50 years. Trades at a decent 16x earnings. JNJ faces many lawsuits, but they staunchly defend themselves through appeals. (Analysts’ price target is $154.41)
BUY
BUY
December 19, 2019
Given the opiate crisis They have three businesses-- so they're not volatile. Yes, they have issues with talcum, but have been winning those lawsuits. JNJ wasn't as big into opiates as other companies.
Show full opinionHide full opinionGiven the opiate crisis They have three businesses-- so they're not volatile. Yes, they have issues with talcum, but have been winning those lawsuits. JNJ wasn't as big into opiates as other companies.
BUY
BUY
December 18, 2019
SYK vs. JNJ SYK makes medical products while JNJ also produces that plus pharma and personal care products, but are fighting talcum powder lawsuits that will persist. Despite this, he much prefers JNJ due to better diversification and valuation. But wait for a better entry point.
TOP PICK
TOP PICK
December 16, 2019
Breaking news: found not guilty of misleading the public with its baby powder. A behemoth, well-diversified trading at an attractive 16x earnings and 5% free cash flow yield. A defensive name today. (Analysts’ price target is $150.28)
Show full opinionHide full opinionBreaking news: found not guilty of misleading the public with its baby powder. A behemoth, well-diversified trading at an attractive 16x earnings and 5% free cash flow yield. A defensive name today. (Analysts’ price target is $150.28)
TOP PICK
TOP PICK
December 11, 2019
If you look at the aggregate liabilities of the talcum powder legal issue, the market has over-estimated the impact on the company, he believes. The litigation could be on-going for years to come and the time value of money works in their favour. Yield 2.69% (Analysts’ price target is $150.28)
Show full opinionHide full opinionIf you look at the aggregate liabilities of the talcum powder legal issue, the market has over-estimated the impact on the company, he believes. The litigation could be on-going for years to come and the time value of money works in their favour. Yield 2.69% (Analysts’ price target is $150.28)
TOP PICK
TOP PICK
December 5, 2019
The drug space all have huge upsides. He has owned it for quite some time. Model rice is $185.42 which is a 33% upside. There is a lot of value here. (Analysts’ price target is $150.39)
Show full opinionHide full opinionThe drug space all have huge upsides. He has owned it for quite some time. Model rice is $185.42 which is a 33% upside. There is a lot of value here. (Analysts’ price target is $150.39)
DON'T BUY
DON'T BUY
November 21, 2019
JNJ vs PG He'd choose PG. JNJ has lawsuits still hanging around. Since mid-summer of 2018, JNJ has underperformed PG. Watch out for valuations. PG is trading at 24x, with a 7% growth rate. PG is the largest consumer name out there and will continue to grow.
Show full opinionHide full opinionJNJ vs PG He'd choose PG. JNJ has lawsuits still hanging around. Since mid-summer of 2018, JNJ has underperformed PG. Watch out for valuations. PG is trading at 24x, with a 7% growth rate. PG is the largest consumer name out there and will continue to grow.
TOP PICK
TOP PICK
November 19, 2019
It's spent time building a base and is ready to move higher. Yes, headline news is a risk. He believes it will move higher. (Analysts’ price target is $150.39)
Show full opinionHide full opinionIt's spent time building a base and is ready to move higher. Yes, headline news is a risk. He believes it will move higher. (Analysts’ price target is $150.39)
COMMENT
COMMENT
November 7, 2019
High opinion of the company. Will be able to work through legal troubles. One-stop shop with pharma, consumer. Good brand names that will weather the storm. Earnings powerhouse. Good dividend. Short-term bumpiness, but well managed. Yield is 2.9%.
Show full opinionHide full opinionHigh opinion of the company. Will be able to work through legal troubles. One-stop shop with pharma, consumer. Good brand names that will weather the storm. Earnings powerhouse. Good dividend. Short-term bumpiness, but well managed. Yield is 2.9%.
BUY WEAKNESS
BUY WEAKNESS
November 5, 2019
The pharma sector. Any picks? Pharma's problem is the US election cycle when candidates always bash big pharma. But these stocks are not expensive now, like JNJ which boasts 3 divisions (consumer, medical devices and pharma); and Novo Nordisk, which offers a diabetes pill and obesity pill. Buy a small position now as well as when they pull back during the election campaign, and certainly after the election. NVO increases its dividend perennially. The Dems and Republicans are equally critical of pharma.
The pharma sector. Any picks? Pharma's problem is the US election cycle when candidates always bash big pharma. But these stocks are not expensive now, like JNJ which boasts 3 divisions (consumer, medical devices and pharma); and Novo Nordisk, which offers a diabetes pill and obesity pill. Buy a small position now as well as when they pull back during the election campaign, and certainly after the election. NVO increases its dividend perennially. The Dems and Republicans are equally critical of pharma.
DON'T BUY
DON'T BUY
October 17, 2019
Wouldn't be a buyer at almost any price. Too much of an unknown with asbestos in talc, opioids, etc. Operationally, doing fine. But unknown legal liabilities in front of them, which often lead to a contraction of valuation.
Show full opinionHide full opinionWouldn't be a buyer at almost any price. Too much of an unknown with asbestos in talc, opioids, etc. Operationally, doing fine. But unknown legal liabilities in front of them, which often lead to a contraction of valuation.
TOP PICK
TOP PICK
October 15, 2019
$170 is his model price, meaning 30% upside. Due to the asbestos lawsuit, this is now a good opportunity. Pays a good dividend. (Analysts’ price target is $148.84)
Show full opinionHide full opinion$170 is his model price, meaning 30% upside. Due to the asbestos lawsuit, this is now a good opportunity. Pays a good dividend. (Analysts’ price target is $148.84)
COMMENT
COMMENT
October 9, 2019
She's done very well with it. Litigation about opiates is the overhang, and just got a negative ruling on their anti-psychotic drug. Their drugs are doing well, but there are a lot of negative headlines. They may continue selling off troublesome drugs. They remain very profitable but also volatile.
Show full opinionHide full opinionShe's done very well with it. Litigation about opiates is the overhang, and just got a negative ruling on their anti-psychotic drug. Their drugs are doing well, but there are a lot of negative headlines. They may continue selling off troublesome drugs. They remain very profitable but also volatile.
TOP PICK
TOP PICK
October 7, 2019
Heath care stocks have not been in favour. JNJ-N has been in the penalty box with the opioid lawsuits. They only had 1% of the sales in this, however. (Analysts’ price target is $148.53)
Show full opinionHide full opinionHeath care stocks have not been in favour. JNJ-N has been in the penalty box with the opioid lawsuits. They only had 1% of the sales in this, however. (Analysts’ price target is $148.53)
BUY WEAKNESS
BUY WEAKNESS
September 6, 2019
The talcum and now opiod crisis will continue to cause them to pay out until the regulators are satisfied. He would be a buyer on weakness.
Show full opinionHide full opinionThe talcum and now opiod crisis will continue to cause them to pay out until the regulators are satisfied. He would be a buyer on weakness.
DON'T BUY
DON'T BUY
August 27, 2019
The talcum power and opioid issues are being worked out. If you extrapolate what could come from other states, it could become a real issue. There was knowledge on the talcum issue for years. He would stay away from this.
Show full opinionHide full opinionThe talcum power and opioid issues are being worked out. If you extrapolate what could come from other states, it could become a real issue. There was knowledge on the talcum issue for years. He would stay away from this.
Johnson & Johnson(JNJ-N) Rating
Ranking : 5 out of 5
Bullish - Buy Signals / Votes : 12
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 5
Total Signals / Votes : 17
Johnson & Johnson(JNJ-N) Frequently Asked Questions
What is Johnson & Johnson stock symbol?
Johnson & Johnson is a American stock, trading under the symbol JNJ-N on the New York Stock Exchange (JNJ). It is usually referred to as NYSE:JNJ or JNJ-N
Is Johnson & Johnson a buy or a sell?
In the last year, 17 stock analysts published opinions about JNJ-N. 12 analysts recommended to BUY the stock. 5 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Johnson & Johnson.
Is Johnson & Johnson a good investment or a top pick?
Johnson & Johnson was recommended as a Top Pick by Christine Poole on 2020-07-16. Read the latest stock experts ratings for Johnson & Johnson.
Why is Johnson & Johnson stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Johnson & Johnson worth watching?
17 stock analysts on Stockchase covered Johnson & Johnson In the last year. It is a trending stock that is worth watching.
What is Johnson & Johnson stock price?
On 2020-08-06, Johnson & Johnson (JNJ-N) stock closed at a price of $147.55.
Owns JNJ instead of Pfizer, because she likes its diversity, and its product pipeline is strong. PFE has a strong balance sheet, but JNJ's is stronger. JNJ's medical device side is recovering nicely, plus they were able to give guidance at a time when many companies can't.